Table 4. Time to parasitemia following each dose of DP by mother’s IPTp treatment arm overall and stratified by infant sex.
| Sex | Mother’s IPTp treatment arm | Number of doses of DP | Number with any parasitemia | Cumulative risk of any parasitemia (95% CI) | HR (95% CI) | p-value | aHRa (95% CI) | p-value |
|---|---|---|---|---|---|---|---|---|
| Allb | SP8w | 742 | 52 | 7.1% (5.5%–9.3%) |
reference | reference | ||
| DP8w | 313 | 25 | 7.5% (5.1%–10.9%) |
1.12 (0.56–2.24) |
0.75 | 1.28 (0.64–2.60) |
0.49 | |
| DP4w | 300 | 43 | 12.8% (9.6%–16.8%) | 2.02 (1.08–3.79) |
0.03 | 2.16 (1.14–4.11) |
0.02 | |
| Female | SP8w | 365 | 21 | 5.9% (3.9%–9.0%) |
reference | reference | ||
| DP8w | 178 | 15 | 8.6% (5.3%–13.9%) |
1.61 (0.58–4.47) |
0.36 | 2.28 (0.78–6.63) |
0.13 | |
| DP4w | 165 | 29 | 17.9% (12.8%–24.7%) |
4.18 (1.64–10.7) |
0.003 | 5.02 (1.90–13.2) |
0.001 | |
| Male | SP8w | 377 | 31 | 8.4% (6.0%–11.7%) |
reference | reference | ||
| DP8w | 160 | 10 | 6.3% (3.5%–11.4%) |
0.77 (0.31–1.92) |
0.58 | 0.72 (0.28–1.80) |
0.48 | |
| DP4w | 178 | 14 | 8.0% (4.8%–11.2%) |
0.95 (0.41–2.20) |
0.91 | 0.91 (0.39–2.10) |
0.83 | |
aAdjusted for maternal age, gravidity, LAMP status at enrolment, and maternal clustering for twin gestation.
bInteraction p-value between female sex and IPTp arm: 0.31 for ITPp-DP8w; 0.02 for IPTp-DP4w.
Abbreviations: aHR, adjusted hazard ratio; DP, dihydroartemisinin-piperaquine; DP4w, IPTp-DP every 4 weeks; DP8w, IPTp-DP given every 8 weeks; HR, hazard ratio; IPTp, intermittent preventive treatment of malaria in pregnancy; LAMP, loop-mediated isothermal amplification; SP8w, IPTp-SP given every 8 weeks.